A computational workflow for analysis of missense mutations in precision oncology

Investor logo
Investor logo
Investor logo

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Science. Official publication website can be found on muni.cz.
Authors

KHAN Rayyan Tariq POKORNÁ Petra DVORSKÝ Jan BORKO Simeon AREFIEV Ihor PLANAS IGLESIAS Joan DOBIÁŠ Adam RANGEL PAMPLONA PIZARRO PINTO José Gaspar SZOTKOWSKÁ Veronika ŠTĚRBA Jaroslav SLABÝ Ondřej DAMBORSKÝ Jiří MAZURENKO Stanislav BEDNÁŘ David

Year of publication 2024
Type Article in Periodical
Magazine / Source JOURNAL OF CHEMINFORMATICS
MU Faculty or unit

Faculty of Science

Citation
web https://jcheminf.biomedcentral.com/articles/10.1186/s13321-024-00876-3
Doi http://dx.doi.org/10.1186/s13321-024-00876-3
Keywords Bioinformatics; Cancer; Function; High-performance computing; Machine learning; Molecular modelling; Oncology; Personalised medicine; Single nucleotide polymorphism; Stability; Treatment
Attached files
Description Every year, more than 19 million cancer cases are diagnosed, and this number continues to increase annually. Since standard treatment options have varying success rates for different types of cancer, understanding the biology of an individual's tumour becomes crucial, especially for cases that are difficult to treat. Personalised high-throughput profiling, using next-generation sequencing, allows for a comprehensive examination of biopsy specimens. Furthermore, the widespread use of this technology has generated a wealth of information on cancer-specific gene alterations. However, there exists a significant gap between identified alterations and their proven impact on protein function. Here, we present a bioinformatics pipeline that enables fast analysis of a missense mutation’s effect on stability and function in known oncogenic proteins. This pipeline is coupled with a predictor that summarises the outputs of different tools used throughout the pipeline, providing a single probability score, achieving a balanced accuracy above 86%. The pipeline incorporates a virtual screening method to suggest potential FDA/EMA-approved drugs to be considered for treatment. We showcase three case studies to demonstrate the timely utility of this pipeline. To facilitate access and analysis of cancer-related mutations, we have packaged the pipeline as a web server, which is freely available at https://loschmidt.chemi.muni.cz/predictonco/.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.